{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:00:17Z","timestamp":1788447617207,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109416","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:04:47Z","timestamp":1776575087000},"page":"109416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non\u2013small cell lung cancer: exploratory analysis of a prospective observational study"],"prefix":"10.1016","volume":"216","author":[{"given":"Takashi","family":"Kurosaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Uchibori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109416_b0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109416_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2026.109416_b0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East asian patients with ALK-positive advanced non-small cell lung cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109416_b0025","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0030","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109416_b0035","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cllc.2020.08.003","article-title":"Immunotherapy treatment patterns and outcomes among ALK-positive patients with non-small-cell lung cancer","volume":"22","author":"Jahanzeb","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2026.109416_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113404","article-title":"Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies","volume":"195","author":"Nuccio","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2021.11.011","article-title":"Association of tumour burden with the efficacy of programmed cell death-1\/programmed cell death ligand-1 inhibitors for treatment-na\u00efve advanced non-small-cell lung cancer","volume":"161","author":"Suzuki","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0070","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0075","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41467-017-00925-6","article-title":"Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration","volume":"8","author":"Gordon-Alonso","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2026.109416_b0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","article-title":"A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0085","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lungcan.2026.109416_b0090","first-page":"3827","article-title":"Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion","volume":"19","author":"Shang","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lungcan.2026.109416_b0095","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2012resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006243","article-title":"Heterogeneity of tumor immune microenvironment of EGFR\/ALK-positive tumors versus EGFR\/ALK-negative tumors in resected brain metastases from lung adenocarcinoma","volume":"11","author":"Xiao","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0110","doi-asserted-by":"crossref","unstructured":"Baek S, Sung E, Kim G, et al. Single-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer. Cancer Commun (Lond) 2025. Epub ahead of print. doi: 10.1002\/cac2.12658.","DOI":"10.1101\/2024.09.24.614708"},{"key":"10.1016\/j.lungcan.2026.109416_b0115","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0120","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration","volume":"22","author":"Ock","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0125","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor immune microenvironment during epithelial-mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0130","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","article-title":"Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma","volume":"22","author":"Lou","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0135","doi-asserted-by":"crossref","first-page":"33316","DOI":"10.18632\/oncotarget.8955","article-title":"Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1","volume":"7","author":"Voena","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109416_b0140","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2026.109416_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174021","article-title":"Angiopoietin inhibitors: a review on targeting tumor angiogenesis","volume":"899","author":"Parmar","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109416_b0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrc2894","article-title":"Targeting the ANGPT-TIE2 pathway in malignancy","volume":"10","author":"Huang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0155","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/ijms21041388","article-title":"Role of VEGFs\/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models","volume":"21","author":"Ceci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2026.109416_b0160","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109416_b0165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2026.109416_b0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.lungcan.2026.109416_b0175","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lungcan.2026.109416_b0180","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","article-title":"Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0185","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109416_b0190","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109416_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2018.02.004","article-title":"Clinicopathologic features and immune microenvironment of non-small-cell lung cancer with primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"19","author":"Takashima","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109416_b0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41698-023-00355-2","article-title":"Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity","volume":"7","author":"Kleczko","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0210","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/2326-6066.CIR-15-0089","article-title":"Efficacy of a cancer vaccine against ALK-rearranged lung tumors","volume":"3","author":"Voena","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2026.109416_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216062","article-title":"Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response","volume":"556","author":"Kleczko","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2026.109416_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109416_b0225","article-title":"A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial","volume":"40(16_suppl):9074","author":"Arrieta","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109416_b0230","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1158\/1078-0432.CCR-14-1905","article-title":"Stromal CD8+ T-cell density\u2014a promising supplement to TNM staging in non-small cell lung cancer","volume":"21","author":"Donnem","year":"2015","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:22:56Z","timestamp":1782663776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"alternative-id":["S0169500226004770"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109416","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non\u2013small cell lung cancer: exploratory analysis of a prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109416"}}